CytomX Therapeutics
CTMX
98 hedge funds and large institutions have $79.5M invested in CytomX Therapeutics in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 28 reducing their positions, and 40 closing their positions.
7% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 28
12.42% less ownership
Funds ownership: 82.07% → 69.65% (-12%)
18% less funds holding
Funds holding: 119 → 98 (-21)
45% less capital invested
Capital invested by funds: $143M → $79.5M (-$63.8M)
48% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$2.43M |
| 2 |
NM
Newtyn Management
New York
|
+$2.06M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.02M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.83M |
| 5 |
Renaissance Technologies
New York
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6.06M |
| 2 |
RI
RTW Investments
New York
|
-$5.61M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$3.45M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.1M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.87M |
CTMX Hedge Fund Activity: Q2 2022 in Review
98 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2022, worth a combined $79.5M — down 45% from $143M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of CTMX and 21 opened new positions — a net loss of 19 holders — while 28 trimmed existing stakes and 26 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $2.43M. The largest seller was BlackRock, cutting an estimated $6.06M.
- 98 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2022, down from 119 in Q1 2022.
- Funds reported $79.5M of CytomX Therapeutics stock for Q2 2022, down 45% quarter-over-quarter.
- 21 funds opened new CytomX Therapeutics positions in Q2 2022 and 40 closed out, a net change of -19 holders.
- The largest CytomX Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $2.43M added.
- The largest CytomX Therapeutics seller in Q2 2022 was BlackRock, an estimated $6.06M sold.
Based on aggregated 13F filings for Q2 2022.